Growth arrest of Epstein-Barr virus immortalized B lymphocytes by adenovirus-delivered ribozymes

Shuang Huang, Dwayne Stupack, Patricia Mathias, Yibing Wang, Glen Nemerow

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Epstein-Barr virus (EBV) infection is associated with several human diseases that involve unrestricted proliferation of B lymphocytes. EBV nuclear antigen 1 (EBNA-1) is expressed in all EBV-infected cells and plays an essential role in persistence of the EBV genome. EBNA-1 has also been reported to have oncogenic potential. As an approach for treating EBV infections, we examined the capacity of EBNA-1 ribozymes delivered by recombinant adenoviruses to suppress EBNA-1 expression and to block virus- induced B cell proliferation. In contrast to primary B cells, EBV-transformed B lymphoblastoid cell lines expressed αv integrins, the adenovirus internalization receptors, and were also susceptible to adenovirus-mediated gene delivery. Adenovirus delivery of a specific ribozyme (RZ1) to lymphoblastoid cell lines, suppressed EBNA-1 mRNA and protein expression, significantly reduced the number of EBV genomes, and nearly abolished cell proliferation in low serum. Adenovirus delivery of RZ1 also prevented EBV infection of an established EBV-negative B cell line. These studies demonstrate the potential use of adenovirus-encoded ribozymes to treat EBV- induced lymphoproliferative disorders.

Original languageEnglish (US)
Pages (from-to)8156-8161
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume94
Issue number15
DOIs
StatePublished - Jul 22 1997

Fingerprint

Catalytic RNA
Epstein-Barr Virus Nuclear Antigens
Human Herpesvirus 4
Adenoviridae
B-Lymphocytes
Epstein-Barr Virus Infections
Growth
Cell Line
Cell Proliferation
Genome
Lymphoproliferative Disorders
Integrins
Viruses
Messenger RNA
Serum
Genes
Proteins

ASJC Scopus subject areas

  • Genetics
  • General

Cite this

Growth arrest of Epstein-Barr virus immortalized B lymphocytes by adenovirus-delivered ribozymes. / Huang, Shuang; Stupack, Dwayne; Mathias, Patricia; Wang, Yibing; Nemerow, Glen.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 94, No. 15, 22.07.1997, p. 8156-8161.

Research output: Contribution to journalArticle

Huang, Shuang ; Stupack, Dwayne ; Mathias, Patricia ; Wang, Yibing ; Nemerow, Glen. / Growth arrest of Epstein-Barr virus immortalized B lymphocytes by adenovirus-delivered ribozymes. In: Proceedings of the National Academy of Sciences of the United States of America. 1997 ; Vol. 94, No. 15. pp. 8156-8161.
@article{4a4eee392d564f7b90246dcdb637d5ba,
title = "Growth arrest of Epstein-Barr virus immortalized B lymphocytes by adenovirus-delivered ribozymes",
abstract = "Epstein-Barr virus (EBV) infection is associated with several human diseases that involve unrestricted proliferation of B lymphocytes. EBV nuclear antigen 1 (EBNA-1) is expressed in all EBV-infected cells and plays an essential role in persistence of the EBV genome. EBNA-1 has also been reported to have oncogenic potential. As an approach for treating EBV infections, we examined the capacity of EBNA-1 ribozymes delivered by recombinant adenoviruses to suppress EBNA-1 expression and to block virus- induced B cell proliferation. In contrast to primary B cells, EBV-transformed B lymphoblastoid cell lines expressed αv integrins, the adenovirus internalization receptors, and were also susceptible to adenovirus-mediated gene delivery. Adenovirus delivery of a specific ribozyme (RZ1) to lymphoblastoid cell lines, suppressed EBNA-1 mRNA and protein expression, significantly reduced the number of EBV genomes, and nearly abolished cell proliferation in low serum. Adenovirus delivery of RZ1 also prevented EBV infection of an established EBV-negative B cell line. These studies demonstrate the potential use of adenovirus-encoded ribozymes to treat EBV- induced lymphoproliferative disorders.",
author = "Shuang Huang and Dwayne Stupack and Patricia Mathias and Yibing Wang and Glen Nemerow",
year = "1997",
month = "7",
day = "22",
doi = "10.1073/pnas.94.15.8156",
language = "English (US)",
volume = "94",
pages = "8156--8161",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "15",

}

TY - JOUR

T1 - Growth arrest of Epstein-Barr virus immortalized B lymphocytes by adenovirus-delivered ribozymes

AU - Huang, Shuang

AU - Stupack, Dwayne

AU - Mathias, Patricia

AU - Wang, Yibing

AU - Nemerow, Glen

PY - 1997/7/22

Y1 - 1997/7/22

N2 - Epstein-Barr virus (EBV) infection is associated with several human diseases that involve unrestricted proliferation of B lymphocytes. EBV nuclear antigen 1 (EBNA-1) is expressed in all EBV-infected cells and plays an essential role in persistence of the EBV genome. EBNA-1 has also been reported to have oncogenic potential. As an approach for treating EBV infections, we examined the capacity of EBNA-1 ribozymes delivered by recombinant adenoviruses to suppress EBNA-1 expression and to block virus- induced B cell proliferation. In contrast to primary B cells, EBV-transformed B lymphoblastoid cell lines expressed αv integrins, the adenovirus internalization receptors, and were also susceptible to adenovirus-mediated gene delivery. Adenovirus delivery of a specific ribozyme (RZ1) to lymphoblastoid cell lines, suppressed EBNA-1 mRNA and protein expression, significantly reduced the number of EBV genomes, and nearly abolished cell proliferation in low serum. Adenovirus delivery of RZ1 also prevented EBV infection of an established EBV-negative B cell line. These studies demonstrate the potential use of adenovirus-encoded ribozymes to treat EBV- induced lymphoproliferative disorders.

AB - Epstein-Barr virus (EBV) infection is associated with several human diseases that involve unrestricted proliferation of B lymphocytes. EBV nuclear antigen 1 (EBNA-1) is expressed in all EBV-infected cells and plays an essential role in persistence of the EBV genome. EBNA-1 has also been reported to have oncogenic potential. As an approach for treating EBV infections, we examined the capacity of EBNA-1 ribozymes delivered by recombinant adenoviruses to suppress EBNA-1 expression and to block virus- induced B cell proliferation. In contrast to primary B cells, EBV-transformed B lymphoblastoid cell lines expressed αv integrins, the adenovirus internalization receptors, and were also susceptible to adenovirus-mediated gene delivery. Adenovirus delivery of a specific ribozyme (RZ1) to lymphoblastoid cell lines, suppressed EBNA-1 mRNA and protein expression, significantly reduced the number of EBV genomes, and nearly abolished cell proliferation in low serum. Adenovirus delivery of RZ1 also prevented EBV infection of an established EBV-negative B cell line. These studies demonstrate the potential use of adenovirus-encoded ribozymes to treat EBV- induced lymphoproliferative disorders.

UR - http://www.scopus.com/inward/record.url?scp=0030759829&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030759829&partnerID=8YFLogxK

U2 - 10.1073/pnas.94.15.8156

DO - 10.1073/pnas.94.15.8156

M3 - Article

C2 - 9223331

AN - SCOPUS:0030759829

VL - 94

SP - 8156

EP - 8161

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 15

ER -